Emanuel Petricoin, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), received funding for the project: “Protein Pathway Activation Based Signaling Mapping of Head And Neck Cancers.”

CAPMM researchers will receive laser microdissected tumour samples from banked Formalin-Fixed Paraffin-Embedded (FFPE) clinical biopsy samples from patients with HPV‐positive head and neck cancers who were treated for newly diagnosed disease.

The researchers will utilize comprehensive reverse‐phase protein microarray (RPPA)-based analysis of 170 pre‐specified proteins and phosphoproteins involved in inflammation pathways, DNA damage and repair pathways, reactive oxygen species pathways, mitophagy pathways, cell survival and apoptosis pathways. 

Petricoin received $63,640 from Inova Healthcare for this research. Funding began in May 2024 and will end in May 2025.

Source: George Mason University